Cargando…
The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes
Objective. Sclerostin is a Wnt inhibitor produced specifically by osteocytes. However, it is not currently clear whether renal dysfunction has an effect on circulating sclerostin level in patients with type 2 diabetes. The aim of the study was to evaluate this relationship. Design and Patients. We c...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099222/ https://www.ncbi.nlm.nih.gov/pubmed/25053944 http://dx.doi.org/10.1155/2014/715908 |
_version_ | 1782326458525417472 |
---|---|
author | Kim, Se Hwa Yoon, Soo Young Lim, Sung-Kil Rhee, Yumie |
author_facet | Kim, Se Hwa Yoon, Soo Young Lim, Sung-Kil Rhee, Yumie |
author_sort | Kim, Se Hwa |
collection | PubMed |
description | Objective. Sclerostin is a Wnt inhibitor produced specifically by osteocytes. However, it is not currently clear whether renal dysfunction has an effect on circulating sclerostin level in patients with type 2 diabetes. The aim of the study was to evaluate this relationship. Design and Patients. We conducted a cross-sectional observational study of 302 type 2 diabetic patients with or without chronic kidney disease. Serum sclerostin level was analyzed by ELISA, and renal function was assessed by estimated glomerular filtration rate (eGFR) using chronic kidney disease epidemiology collaboration (CKD-EPI) equation. Results. There was a strong correlation between sclerostin level with renal function presented as serum creatinine (r = 0.745, P < 0.001) and eGFR (r = −0.590, P < 0.001). Serum sclerostin level was significantly higher in patients with CKD-G3 stage than those with CKD-G1/2 stages after adjusting for age, sex, and BMI (P = 0.011). Patients with CKD-G4/5 stages had dramatically increased level of circulating sclerostin. Multiple regression analyses found that age, sex, and eGFR were independent determining factors for circulating sclerostin level. Conclusion. Our data showed that serum sclerostin levels start to increase in diabetic patients with CKD-G3 stage. Further studies are needed to establish the potential role of elevated sclerostin in diabetic patients with CKD. |
format | Online Article Text |
id | pubmed-4099222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40992222014-07-22 The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes Kim, Se Hwa Yoon, Soo Young Lim, Sung-Kil Rhee, Yumie Int J Endocrinol Research Article Objective. Sclerostin is a Wnt inhibitor produced specifically by osteocytes. However, it is not currently clear whether renal dysfunction has an effect on circulating sclerostin level in patients with type 2 diabetes. The aim of the study was to evaluate this relationship. Design and Patients. We conducted a cross-sectional observational study of 302 type 2 diabetic patients with or without chronic kidney disease. Serum sclerostin level was analyzed by ELISA, and renal function was assessed by estimated glomerular filtration rate (eGFR) using chronic kidney disease epidemiology collaboration (CKD-EPI) equation. Results. There was a strong correlation between sclerostin level with renal function presented as serum creatinine (r = 0.745, P < 0.001) and eGFR (r = −0.590, P < 0.001). Serum sclerostin level was significantly higher in patients with CKD-G3 stage than those with CKD-G1/2 stages after adjusting for age, sex, and BMI (P = 0.011). Patients with CKD-G4/5 stages had dramatically increased level of circulating sclerostin. Multiple regression analyses found that age, sex, and eGFR were independent determining factors for circulating sclerostin level. Conclusion. Our data showed that serum sclerostin levels start to increase in diabetic patients with CKD-G3 stage. Further studies are needed to establish the potential role of elevated sclerostin in diabetic patients with CKD. Hindawi Publishing Corporation 2014 2014-06-26 /pmc/articles/PMC4099222/ /pubmed/25053944 http://dx.doi.org/10.1155/2014/715908 Text en Copyright © 2014 Se Hwa Kim et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Kim, Se Hwa Yoon, Soo Young Lim, Sung-Kil Rhee, Yumie The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes |
title | The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes |
title_full | The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes |
title_fullStr | The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes |
title_full_unstemmed | The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes |
title_short | The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes |
title_sort | effect of renal dysfunction on circulating sclerostin level in patients with type 2 diabetes |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099222/ https://www.ncbi.nlm.nih.gov/pubmed/25053944 http://dx.doi.org/10.1155/2014/715908 |
work_keys_str_mv | AT kimsehwa theeffectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT yoonsooyoung theeffectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT limsungkil theeffectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT rheeyumie theeffectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT kimsehwa effectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT yoonsooyoung effectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT limsungkil effectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes AT rheeyumie effectofrenaldysfunctiononcirculatingsclerostinlevelinpatientswithtype2diabetes |